TDC
NAGE

Thompson Davis & Co’s Niagen Bioscience NAGE Stock Holding History

Thompson Davis & Co’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,350
Closed -$149K – 735
2017
Q4 		$149K Sell
25,350
-4,400
-15% -$23.8K 0.35% 68
2017
Q3 		$128K Buy
+29,750
New +$109K 0.23% 100

Other funds holding NAGE

IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Thompson Davis & Co's NAGE Position: Q1 2018 in Review

Thompson Davis & Co sold out of Niagen Bioscience (NAGE) in Q1 2018, closing a stake of 25,350 shares — an estimated $149K sold.

Thompson Davis & Co first reported a position in NAGE in Q3 2017 and held it in 2 quarters. The position peaked at $149K in Q4 2017. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2018.

  • Thompson Davis & Co reported no remaining Niagen Bioscience position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 25,350 Niagen Bioscience shares in Q1 2018, an estimated $149K.
  • Thompson Davis & Co first reported a position in Niagen Bioscience in Q3 2017 and held it in 2 quarters.
  • Thompson Davis & Co's Niagen Bioscience position peaked at $149K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.